HomeCompareSTAB vs DIVO

STAB vs DIVO: Dividend Comparison 2026

STAB yields 500000.00% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STAB wins by $4.663521010693878e+33M in total portfolio value
10 years
STAB
STAB
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full STAB calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — STAB vs DIVO

📍 STAB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTABDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STAB + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STAB pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STAB
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, STAB beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STAB + DIVO for your $10,000?

STAB: 50%DIVO: 50%
100% DIVO50/50100% STAB
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STAB buys
0
DIVO buys
0
No recent congressional trades found for STAB or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTABDIVO
Forward yield500000.00%6.62%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.663521010693878e+33M$31.0K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$1,008.47
Total dividends collected$4.6634009849658873e+33M$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: STAB vs DIVO ($10,000, DRIP)

YearSTAB PortfolioSTAB Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,362$661.96+$50.00MSTAB
2$233,748,371,262$233,694,859,813.08$12,860$702.91+$233748.36MSTAB
3$1,021,074,511,412,696$1,020,824,400,655,446.10$14,504$743.56+$1021074511.40MSTAB
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$16,303$783.73+$4168597328794.94MSTAB
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$18,268$823.31+$15905475114600664.00MSTAB
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$20,408$862.17+$56718938532531060736.00MSTAB
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$22,737$900.20+$1.8903180743562385e+23MSTAB
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$25,266$937.31+$5.8879981047651824e+26MSTAB
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$28,008$973.42+$1.7140642681147225e+30MSTAB
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$30,977$1,008.47+$4.663521010693878e+33MSTAB

STAB vs DIVO: Complete Analysis 2026

STABStock

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.

Full STAB Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this STAB vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STAB vs SCHDSTAB vs JEPISTAB vs OSTAB vs KOSTAB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.